Anthony W Castleberry1, Judson B Williams1, Mani A Daneshmand1, Emily Honeycutt1, Linda K Shaw1, Zainab Samad1, Renato D Lopes1, John H Alexander1, Joseph P Mathew1, Eric J Velazquez1, Carmelo A Milano1, Peter K Smith2. 1. From the Department of Surgery; The Division of Cardiovascular and Thoracic Surgery (A.W.C., J.B.W., M.A.D., C.A.M., P.K.S.); Duke Clinical Research Institute (J.B.W., E.H., L.K.S., R.D.L., J.H.A., E.J.V.); Department of Medicine, Division of Cardiology (Z.S., R.D.L., J.H.A., E.J.V.); and Department of Anesthesiology, Division of Cardiothoracic Anesthesiology and Critical Care Medicine (J.P.M.), Duke Medicine, Durham, NC. 2. From the Department of Surgery; The Division of Cardiovascular and Thoracic Surgery (A.W.C., J.B.W., M.A.D., C.A.M., P.K.S.); Duke Clinical Research Institute (J.B.W., E.H., L.K.S., R.D.L., J.H.A., E.J.V.); Department of Medicine, Division of Cardiology (Z.S., R.D.L., J.H.A., E.J.V.); and Department of Anesthesiology, Division of Cardiothoracic Anesthesiology and Critical Care Medicine (J.P.M.), Duke Medicine, Durham, NC. peter.smith@dm.duke.edu.
Abstract
BACKGROUND: The optimal treatment for ischemic mitral regurgitation remains actively debated. Our objective was to evaluate the relationship between ischemic mitral regurgitation treatment strategy and survival. METHODS AND RESULTS: We retrospectively reviewed patients at our institution diagnosed with significant coronary artery disease and moderate or severe ischemic mitral regurgitation from 1990 to 2009, categorized by medical treatment alone, percutaneous coronary intervention, coronary artery bypass grafting (CABG), or CABG plus mitral valve repair or replacement. Kaplan-Meier methods and multivariable Cox proportional hazards analyses were performed to assess the relationship between treatment strategy and survival, with the use of propensity scores to account for nonrandom treatment assignment. A total of 4989 patients were included: medical treatment alone=36%, percutaneous coronary intervention=26%, CABG=33%, and CABG plus mitral valve repair or replacement=5%. Median follow-up was 5.37 years. Compared with medical treatment alone, significantly lower mortality was observed in patients treated with percutaneous coronary intervention (adjusted hazard ratio, 0.83; 95% confidence interval, 0.76-0.92; P=0.0002), CABG (adjusted hazard ratio, 0.56; 95% confidence interval, 0.51-0.62; P<0.0001), and CABG plus mitral valve repair or replacement (adjusted hazard ratio, 0.69; 95% confidence interval, 0.57-0.82; P<0.0001). There was no significant difference in these results based on mitral regurgitation severity. CONCLUSIONS: Patients with significant coronary artery disease and moderate or severe ischemic mitral regurgitation undergoing CABG alone demonstrated the lowest risk of death. CABG with or without mitral valve surgery was associated with lower mortality than either percutaneous coronary intervention or medical treatment alone.
BACKGROUND: The optimal treatment for ischemic mitral regurgitation remains actively debated. Our objective was to evaluate the relationship between ischemic mitral regurgitation treatment strategy and survival. METHODS AND RESULTS: We retrospectively reviewed patients at our institution diagnosed with significant coronary artery disease and moderate or severe ischemic mitral regurgitation from 1990 to 2009, categorized by medical treatment alone, percutaneous coronary intervention, coronary artery bypass grafting (CABG), or CABG plus mitral valve repair or replacement. Kaplan-Meier methods and multivariable Cox proportional hazards analyses were performed to assess the relationship between treatment strategy and survival, with the use of propensity scores to account for nonrandom treatment assignment. A total of 4989 patients were included: medical treatment alone=36%, percutaneous coronary intervention=26%, CABG=33%, and CABG plus mitral valve repair or replacement=5%. Median follow-up was 5.37 years. Compared with medical treatment alone, significantly lower mortality was observed in patients treated with percutaneous coronary intervention (adjusted hazard ratio, 0.83; 95% confidence interval, 0.76-0.92; P=0.0002), CABG (adjusted hazard ratio, 0.56; 95% confidence interval, 0.51-0.62; P<0.0001), and CABG plus mitral valve repair or replacement (adjusted hazard ratio, 0.69; 95% confidence interval, 0.57-0.82; P<0.0001). There was no significant difference in these results based on mitral regurgitation severity. CONCLUSIONS:Patients with significant coronary artery disease and moderate or severe ischemic mitral regurgitation undergoing CABG alone demonstrated the lowest risk of death. CABG with or without mitral valve surgery was associated with lower mortality than either percutaneous coronary intervention or medical treatment alone.
Authors: Michael D Diodato; Marc R Moon; Michael K Pasque; Hendrick B Barner; Nader Moazami; Jennifer S Lawton; Marci S Bailey; Tracey J Guthrie; Bryan F Meyers; Ralph J Damiano Journal: Ann Thorac Surg Date: 2004-09 Impact factor: 4.330
Authors: M S Feinberg; E Schwammenthal; L Shlizerman; A Porter; H Hod; D Friemark; S Matezky; V Boyko; L Mandelzweig; Z Vered; S Behar; A Sagie Journal: Am J Cardiol Date: 2000-11-01 Impact factor: 2.778
Authors: L Aklog; F Filsoufi; K Q Flores; R H Chen; L H Cohn; N S Nathan; J G Byrne; D H Adams Journal: Circulation Date: 2001-09-18 Impact factor: 29.690
Authors: Benjamin H Trichon; Donald D Glower; Linda K Shaw; Christopher H Cabell; Kevin J Anstrom; G Michael Felker; Christopher M O'Connor Journal: Circulation Date: 2003-09-09 Impact factor: 29.690
Authors: Hari R Mallidi; Marc P Pelletier; Jennifer Lamb; Nimesh Desai; Jeri Sever; George T Christakis; Gideon Cohen; Bernard S Goldman; Stephen E Fremes Journal: J Thorac Cardiovasc Surg Date: 2004-03 Impact factor: 5.209
Authors: Zoltan A Szalay; Ali Civelek; Stephen Hohe; Hans-Peter Brunner-LaRocca; Wolf-Peter Klövekorn; Igor Knez; Paul R Vogt; Erwin P Bauer Journal: Eur J Cardiothorac Surg Date: 2003-04 Impact factor: 4.191
Authors: Krzysztof Golba; Krzysztof Mokrzycki; Jaroslaw Drozdz; Alexander Cherniavsky; Krzysztof Wrobel; Bradley J Roberts; Haissam Haddad; Gerald Maurer; Michael Yii; Federico M Asch; Mark D Handschumacher; Thomas A Holly; Roman Przybylski; Irving Kron; Hartzell Schaff; Susan Aston; John Horton; Kerry L Lee; Eric J Velazquez; Paul A Grayburn Journal: Am J Cardiol Date: 2013-09-13 Impact factor: 2.778
Authors: Peter K Smith; John D Puskas; Deborah D Ascheim; Pierre Voisine; Annetine C Gelijns; Alan J Moskowitz; Judy W Hung; Michael K Parides; Gorav Ailawadi; Louis P Perrault; Michael A Acker; Michael Argenziano; Vinod Thourani; James S Gammie; Marissa A Miller; Pierre Pagé; Jessica R Overbey; Emilia Bagiella; François Dagenais; Eugene H Blackstone; Irving L Kron; Daniel J Goldstein; Eric A Rose; Ellen G Moquete; Neal Jeffries; Timothy J Gardner; Patrick T O'Gara; John H Alexander; Robert E Michler Journal: N Engl J Med Date: 2014-11-18 Impact factor: 91.245
Authors: Bart S Ferket; Vinod H Thourani; Pierre Voisine; Samuel F Hohmann; Helena L Chang; Peter K Smith; Robert E Michler; Gorav Ailawadi; Louis P Perrault; Marissa A Miller; Karen O'Sullivan; Stephanie L Mick; Emilia Bagiella; Michael A Acker; Ellen Moquete; Judy W Hung; Jessica R Overbey; Anuradha Lala; Margaret Iraola; James S Gammie; Annetine C Gelijns; Patrick T O'Gara; Alan J Moskowitz Journal: J Thorac Cardiovasc Surg Date: 2019-07-02 Impact factor: 5.209
Authors: Brian C Gulack; Brian R Englum; Anthony W Castleberry; Mani A Daneshmand; Peter K Smith; Louis P Perrault Journal: Ann Cardiothorac Surg Date: 2015-05
Authors: Krzysztof Wrobel; Susanna R Stevens; Robert H Jones; Craig H Selzman; Andre Lamy; Thomas M Beaver; Ljubomir T Djokovic; Nan Wang; Eric J Velazquez; George Sopko; Irving L Kron; J Michael DiMaio; Robert E Michler; Kerry L Lee; Michael Yii; Chua Yeow Leng; Marian Zembala; Jean L Rouleau; Richard C Daly; Hussein R Al-Khalidi Journal: Circulation Date: 2015-08-25 Impact factor: 29.690